Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor02: Trastuzumab deruxtecan in selected HER2-expressing solid tumors
2020-001574-29Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in Nonhematologic neoplasms, cancer and Neoplasm, sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Sep 2020; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasmscancerNeoplasm
Beyond the preview
Go deeper on 2020-001574-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001574-29.